
Donanemab and lecanemab have shown promise in slowing cognitive decline in early Alzheimer's disease, but they also present risks such as ARIA. Further research is needed to assess their long-term safety and efficacy.
disease, donanemab, lecanemab, treatment, alzheimer, effective
disease, donanemab, lecanemab, treatment, alzheimer, effective
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
